MTNB - Earnings call transcript Q1 2022 | Matinas BioPharma Holdings, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to the Matinas BioPharma first quarter 2022 results conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation.

As a reminder, this conference is being recorded. I would now like to turn the conference over to Peter Vozzo, Investor Relations representative for Matinas BioPharma.

begin. may You

Peter Vozzo

financial morning website Matinas Good Early thank for on with you morning, The business Thank is the release first everyone Investors quarter the available our release press BioPharma issued Matinas call. along XXXX joining with we updates. BioPharma you. the a and results, under results this conference section.

Kucinski, be Officer; Chief Officer; Dr. Officer; Chief Development Dr. Speaking Ferguson, Executive and Officer. on Terry Financial Chief Keith today’s Jerry Jabbour, call Medical Terry will Chief Matkovits,

We our expectations Chief this of the be uncertainties. during are listeners also or projections would Business Officer forward-looking available to our Mr. Thomas risks beliefs, and made have Hoover, At call I who may answer Q&A time, remind These involve remarks will questions future. and this state to during management’s like the statements hopes, session. intentions,

call Forward-looking and provisions laws. federal securities Harbor statements pursuant Matinas on current Safe statements on this to differ the materially. of results based could BioPharma’s forward-looking are These made are actual expectations

you should on forward-looking reliance any not undue place result, statements. a As

to These company’s website Investors could the website. posted the documents factors call website are SEC’s section Commission. differ the Some available are also reports in materially files in company’s the forward-looking cause contemplated on Exchange the that actual statements discussed results section. and this Investors of be periodic the will the BioPharma of Matinas from the Securities the and An those of with in to archive in

to now turn question open Jerry. call over a will answer we and session. will remarks, prepared call I company’s the the Following the for

Jerome Jabbour

incredibly join time and substantial will morning, XXXX we quarter make we review today. business an thank Thank XXXX. challenging results you you and This market morning for Peter. business stocks, for during us to have a biotech Despite across financial managed taking progress first update. our our the provide Good to everyone

delivering our to same our reach LNC the new consistent molecules technology disruptive exciting on our the pre-clinical the focused LNC platform and compelling collaborations platform of to and by continued time, data in external delivery and new our clinical data also At encapsulate. to yield advancement continue validate of expanding We pipeline. internal

announced LNC RNA validation of messenger other RNA from pharmaceutical external leader a partners provides of creates and patients. Our which for administration benefit pioneer, BioNTech, with hundreds edge for recently the messenger cutting of could potentially platform clear and therapeutics the opportunity our oral vaccines millions global

nucleic built technology. and Genentech we own provide pre-clinical with acids discovery our data combined further significant proprietary next-generation the LNC Our ongoing drug materials, programs delivery other projects our biological potential upon to delivering capitalize momentum internal around validating with seek for as of the Gilead, and

this Dr. me make able far it’s over the and LNC today stage to on call to Terry all clinical and of have been so Joining are the Matkovits pleasure to to my through Ferguson, assets. the Dr. our guide we us speak updates progress to year turn Matkovits to

Theresa Matkovits

which by is to good B. drug, oral formulation spectrum fungicidal exciting the program, our some very with everyone. and Jerry Thanks developments broad like begin LNC MATXXXX the morning of I’d discussing amphotericin

and patients administered B, administered additional oral MAT of period patients control an already all-oral during trial, Our weeks we X-FC. on also meningitis, three amphotericin with of is a by in patients which receiving ongoing XX-day cryptococcal disease. currently the began of XX group four a from in XXXX. deadly late II a patients HIV first four, evaluation compelling suffering With of this with EnACT four therapy of January cohorts XXXX followed XXXX. studying cohort Cohort XX consolidation MAT of with is of MATXXXX trial four in is data fungal in Cohort MATXXXX Phase are regimen X-FC demonstrated induction IV enrolling the comprised

As discussed the these receive to IV MATXXXX not can have dose since patients highly in group previously, that impact amphotericin in vulnerable of treating the of clinically is meaningful MATXXXX especially do opportunity cohort a any demonstrate great patients oral informative and an this therefore represents patients.

to is as XX% making to include any continues four for safety meet but pleased well a the currently as very on the announcement review of as We Further, enrollment active open of XXXX. are from report treatment expectations. with are anticipated anticipated of our to is very complete label past do We a XXXX patients will data of the month end The this which point and reported the enrolled review XX% cohort. DSMB following trial. at that and, that also been enrolled efficacy the is overall patients the in have be enrollment reviews, cohort the well, to all in this this with doing anticipate not patients review, quarter third good sign third scheduled of line cohort quite reporting data of DSMB early of for the in top quarter in

recently the MATXXXX. Turning program, received follow-up our and MATXXXX application held FDA now we strategy for clinical have productive a of new drug written - concerning support feedback NDA type submission required the confirmatory to C a data the development the regulatory for to meeting with

NDA end end and as of XX% for relapse-free now with meningitis MATXXXX of both a secondary confirmatory a with design development a III induction This support comparing randomized X-FC, filing Critical for pathway official power, based followed therapy elements consolidation III induction indication an treatment to key MATXXXX reflected requirements customary trial. This a in point in registration with with improvement approximately from total of meeting, translating IV streamlined the both consolidation As size evaluate a patients cryptococcal primary single in by with meaningful trial step-down amphotericin a include represents may treatment time which with Phase into as registration of requires and of minutes National meningitis. feature MATXXXX induction the of the XXX considering single Phase of assuming two for the consolidation filing will non-inferiority is pivotal two well also early consolidation indication well adequate upon will which control and of EnACT cryptococcal survival of cause a NDA for X-FC FDA a treatment patients as administered one will a trial registration non-inferiority XX% FDA include point potential meet arm XX trial commence in of weeks through a that Health. Phase the HIV of all for Institutes indication, a design in with and to we later an controlled the meningitis. favor the MATXXXX traditionally III two in trials margin quarter induction finalize the to financial support to week of the administered trial plan We third with registration. continued anticipate XXXX, pivotal III in patients XXXX mortality

key Concurrent regional on the package receiving company We feedback remains discussions third outside pleased in to Looking we registration Agency, European States, MATXXXX and development MATXXXX or of with EMA formal to for United program parties year. a Medicine to a this the to the later for our the we scientific globally. facilitate that report of advice support rights are the a recently expanding the process, interested obtaining with global footprint basis. request anticipate EMA on submitted in in and regulatory

for and part MATXXXX auris MATXXXX MATXXXX on clinical treatment version and MATXXXX of most potential the pre-clinical of the as into mucormycosis our studies been expansion to label drug available, oral invasive fungicidal program As infections. support focused of Candida for in an of management fungal other initiated unlocking safe the cycle the full life planned anti-fungal of previously have potential

today MATXXXX in as deadly as protecting preliminary generated invasive against mucormycosis, amphotericin infection. B data liposomal We date are excited demonstrate to report that fungal effective that is to a

initiated MATXXXX Additional confirmatory Further early auris different quarter preliminary in this in of pre-clinical the Candida and expected of year evaluation are data mucormycosis April XXXX. is strains of ongoing. in third against studies was of

our locations anticipation and NDA during with reached cryptococcal Scientific registration in of with II scale-up MATXXXX development trial support both program Fisher bacterial Phase agreement quarter focused is amikacin XXXX delivering or first conclusion oral the acute Thermo infections. and Finally, planned initially the and of our following only our partner infections, This filing of to for for selected MATXXXX the company is chronic and in for This for meningitis, the working MATXXXX, NTM the platform pulmonary mycobacterial, to an development, oral commercial we non-tuberculous disseminated. under all potential capabilities manufacturing MATXXXX. a plasmids, logistics more viral objective. product vectors, solutions, CGMP around Fisher of first world, turn and to LNC with look achieve to like to integrated alongside for packaging. of and experienced forward biologics, to trial manufacturing technology, than CMC and I’d across step and significant services, forward and a XX APIs, end-to-end clinical the Thermo now including phases treatment on well-respected treat and formulation, Scientific, provides our such aminoglycoside delivered

our which studies to of two LNC was to events Our safety several are the volunteers team with we ascending any we good formulation no single an longer meantime, drug share the efficacy There in completed to proportional associated study renal formulated Phase findings in of doses oral ototoxicity only From trial the in dose drugs. the the seen the relatively the were should trial legacy our at study. our planned this exception to two with high dose clinical and absorption morning. top mild of generally a progress and of in administered tox and with hours. results our milligrams MATXXXX rapid dose formulation or approximately or in very at higher what XXXX made - perspective, increases demonstrating oral No has significant administered, any that milligrams, most are able of for advance confirmed line maximal Overall, the pre-clinical observed increases increased not discontinuations concentration dosing via adverse IV of amikacin. significant MATXXXX seen toxicities MATXXXX trials. and adverse in inconsistent additional pharmacokinetic trial, small serious MATXXXX was program administration delivery. no in study. with evidence levels there critical same doses enable recently to was with dose other time an with there or LNC the term with a seen in absorption There pleased with tested events diarrhea we which optimized required observed this earlier Overall, amikacin the results along with were healthy common have with increase molecule dose, were severity with of of moderate with the with In II you XXX XXX, XXX the MATXXXX the from evaluated completed

levels platform the submitting circulating these Phase LNC in external amikacin to data than a over to which is to favorable completion administered planned like XXXX now tox FDA the program with turn discussing profile. and safety some commence next position IV and development Terry Dr. Importantly, collaborations. MATXXXX. developments our with for term with II potentially anticipate and of Cystic steps Ferguson with to exciting significantly discuss program of plasma forward long amikacin, a who more call our I’d in expected and being Foundation We our lower we MATXXXX to ongoing following Fibrosis studies will as of the plan translate were to a look

Terry Ferguson

and of take our few update I’d made some substantial on Terry. progress the a we’ve year. like Thanks collaborations minutes to external already research to this everyone

Infectious University we lung formulation improved of and second vivo two, Institute improved lung in Hill mice SARS-CoV-X. in performed North with recently day and loss NIAID, remdesivir congestion infected study at of SARS-CoV-X. - oral from the significantly of Carolina an the oral demonstrated reduced in titres the data collaboration Diseases that First, well National LNC study Department and model as Epidemiology significantly at of scores, established The of received remdesivir the Allergy COVID-associated very early weight Chapel as viral of LNC with a in significantly

be the next discussing might reasons: histological first, and still efficacy with data for an and be early remdesivir. formulation of two against otherwise waiting the remdesivir very itself, Gilead. final are NIAID second, are of titres, oral not knockdown important that IV conventional encouraging something will with lung the therapeutic We SARS-CoV-X steps of viral expected and analyses shortly These

for expanded which also has to a be Matinas Next, creating LNC with formulation. fragment specialized compound, Genentech ongoing third a will collaboration oral optimized antibody include its Matinas an

in otherwise it represents not and to enter next For be that this apply exciting oral testing because the withstand this in that a to Matinas, take is months provide anticipated later LNCs GI the hostile environment advantage potential to tract. pre-clinical We particularly project protection will that an results of biologics few with it of the anticipate the able compound formulations fragile would XXXX. of opportunity

some Finally, I’d own the also like of BioNTech perspectives to provide collaboration. on my

aspects one program foundation strong me, the work very gotten external is has a this to in-house For of how of vaccine on attention. of with LNCs most which exciting of builds it lot date a prior not

and different additional techniques a deeper of formulations the and deal collaboration, as own LNC Our the collaborations to delivery us. with a capabilities formulations. of protein and will administration, - associated of systemic with great BioNTech the immunogenic potentially unique flexible LNCs our vaccine nucleic DNA the remdesivir and partnerships breadth and amikacin, turn be that a potential LNC high some of ongoing native enhancement add over we of this understand formulations boosted all takes payloads this complexes more be adverse NIH delivery. with thus learning LNC difficult where establish broader work than payloads is and to IM, for replication, Genentech repeat of system, LNC you an - deliver effective by them complex formulations body by world with of foundation work establish responses following administration the of expertise mucosal plasmids other and and variety enhanced other delivery pipeline with with subtle Gilead with potentially oral proteins, deliver of peptides, of This oral with this of as and target collaboration taken a in tissues. and of and to in shown in of can or about immunization, combine amphotericin intracellular highly you the response both a LNCs into biologics. vaccines humeral and this internal a can protein to antibody of in platform to developing adjuvants, oral, viral successful vaccine. not substantially LNC time, creating create will the platform robust the vaccines, flu to DNA commercial is the that and formulation knowledge inhalation not unique oral and were a LNC internal follow, to robust with us in strong can foundation to even and course forge nuances for both a responses enhanced the molecules nucleic experience opportunity with and be itself realm mucosal our reactions, which antibody much directions, mix and in into stronger mRNA proteins, on the acids sensitive further peptides, a additional stable successfully complexes, with work already of to LNC of oral of package The therapies DNA targets, even oral step vast refining inhibition potential DNA advantage vaccines When both instances that delivering with for whole can subcu, and of persist additional vaccine demonstrated mechanism vivo areas intracellular capabilities vaccine cellular biological of strengths resulting well and delivery our degree for of immune full routes interactions differentiated take cellular cellular allowing prior systemic advantage LNC infections, itself can collaboration and of for own to responses such begin further responses Throughout large have an have to the to more humeral new cellular administration immunity, the creating be of take why the LNC LNC in acid the this exciting plasmids, delivery of delivering vaccines, BioNTech’s

beyond. We’re now during results. the our to additional sharing will Keith on our discuss Kucinski really CFO, who updates Keith? financial call and looking turn forward XXXX will I progress our to over

Keith Kucinski

loss will were headcount development marketable candidates through and on increase and of of XX, XXXX. diluted $X.XX advancing $X.X approximately XX, with fund over million good in to XXXX $X expenses XXXX. we million common first Cash, current projections, the XXXX, net loss the for $X.X million our securities and to reported approximately company Terry sufficient at compared net associated operations people higher March costs for down administrative a same The $X.X cash back and loss first basic per share Thanks has to as the shareholders of call planned $XX.X to December $XX.X shareholders Jerry. XXXX were hand in in that XXXX. and year to period the share XXXX. to on equivalents, General per internal million quarter compared morning quarter were primarily from Research is also product at $X.X turn attributable $X of of expenses cash quarter $X.XX common grown organizational I million is year. of approximately million and and in over diluted million Today, now continue the XXXX. Based development higher or to approximately everyone. the compared of believe first expenses to net period a to in attributable a the of approximately same basic quarter the XXXX due same million,

Jerome Jabbour

so provides future the of other In solutions is significant you technology, nucleic and LNC delivery all critical viral delivery which a molecules safe our medicines the of true effective efficient, summary, and and challenges materials. Thank modalities, especially but by including faced some differentiated acids to mission for and we of Keith. biological to have lipid nanoparticles therapeutics in other platform vectors. unique Embodied and

generate all data our across further We to impressive programs, continue our technology. validating

has keep under its team plan challenging eye managed to strategic conditions. adroitly ball on our in Our collective executing the

has a our platform coming in We are also with delivery effective extremely from additional and of In impact on pleased we the a reporting to of next hungry MATXXXX had cohort catalysts confirmatory pharma data some aligning resultant quarters. giants XXXX, positioned cash a forward milestones patients’ board. With the through ourselves of with positive we four an lining and take foundation numerous EnACT advantage, we to the strong ahead competitive the saving are runway advantage our are the look well lives, building and and for over months. across path several believe we months

to back everyone forward concludes us to apprised forward. journey a the now end progress keeping will look call investors question our grateful facilitate for our to Peter We’re this Operator, This remarks, session. over the turn joining our to exciting and moving I to of answer our on we and as and prepared

Operator

from [Operator instructions] Our first Please ahead. BTIG. question Hazlett Bert with go is

Bert Hazlett

you on I I’ll the the phone, back impressive. with to but of XXXX, progress to formal my terms just - far on without and hear movement come you a them. but Congratulations and Jerry, BioNTech a would toward only the you. of a like and colleagues all have getting ask very number the questions, fairness in to on then I or agreement, Thank anybody, one two such have license the agreement, yourself outline an ahead would in which that. couple love general see too to could or

Jerome Jabbour

the very in about form because The about agreement of Sure, space ability to the very was at The essentially we that’s patients. only last of of not in RNA, to very, optimizing a payments, with with centered result exclusivity, would it to have the learn extensive here in our arriving product. you right deals this, into of are an they to We collaboration, at wanted the trying question, with especially this of beginning of sort the biggest began look technology. vehicles, six find how in doing, to to just our acids, Google be a delivery entire shared are license agreement. intently of that benefit trigger a been specifically wildcard a consist that interest for RNA months, easy so a Bert. both but without can going that real like is us plenty discussions relationship royalties if us, them things to much relationship of looking so this we’re nucleic normal a in to Matinas, and the variety relationship that upfront the appropriate look an triggers, to it’s as milestones, collaborate apply done for questions pretty relationship are also but areas just that license how then that’s in so they’re just associated talking and but it collective then delivery these going going to our visibility them central is There’s this with of messenger value sales important development what are have discussions, the how now foundation specifically, and then broad naming and to messenger understand a of of take focused other space collaboration so work like, together, brings closely to what is, can important license we’re breadth science, The what like letting are both truly and now with begins some the them, remains exclusive a into and obviously kitchen, a of very began and points. there, like a from we it control the think messenger the on to area want multitude there’s which vaccine products. thanks understanding of lot for with a giving relationships, so them areas relationships we’re our about technologies Obviously RNA great fundamental be myself we of other in get that BioNTech on update timing, of appropriate does option with they associated that gives a than can our with continued of Hopefully and around finalize we I BioNTech on the believe deal truly take on on be value call. deep BioNTech at thoughtful, field fundamentally and it of we there’s and now discussions be you believe that seen. that highest that the of attention a particular while it protections precedent quite of the agreement, talking of what the whether has for complex license option a levels Those encouraged between framed. and we’re you of or field something and sense working much the by to Very that, commenting That won’t today’s spirit ago. to broadly no the vaccines, spirit messenger sort how could be of more Ugur of RNA, really place

Bert Hazlett

I’m regard I’ll and the thank you you for your That’s in the just Good additional harmonize of the and after Is is couple with regimen. process ability an with congratulations color, consolidation Then to all in shift remarks, as luck safety those. questions, all-oral did, there helpful. safety on win, air the there, be registrational with very - pretty with on it a A to quoting Could you for things, those so that. over the way a there lot XXXX. discussions? an that you Cohort back on to induction and benchmark is there number readouts side that? and during opening EMA of you that. meaningful, a process upcoming Then the efficacy all to four would mentioned of

Jerome Jabbour

of announcement used the All we Cohort set look as move four so when really of you as certainly to right from with that’s the two around right you package attacks chemically smack to a thrilled all will is can which amphotericin Exactly it’s where then which was any work and of a so it reasonable not MATXXXX, be she extending so a continues sort and that can want at third thanks an to that’s sooner use data we because months, we was big look--and broad FDA, where there Great, to of and big QX, that’s in right, all-oral to position available past, the for win certainly really four, safety safety so a the in encourage upon to study, broaden get well, lead-in, this time more deliver drug you but with certainly so and period a a in Dr. which in a the with complete the with the spectrum there. EnACT I’ll it the soon at is a wins, we even very long putting what a removing two be induction us doubt IV on together EMA. to point, that regimen the comprehensive patients induction valuable year, drug. hospital the them spectrum susceptible also way patients you’re that the Bert. and a mean, most from our then patients to on figure and induction, really the way you’re point on and and that to within then in physicians drug potential let’s did are Then of her of to when have optimizing required never the want of can so a and EMA so big it she’s drug, could about corner it just yes, makes at big win regimen amphotericin, that’s two, cohort of health resistance, win ask of you’re seen cohort. also opportunity safety, beyond we in QX from we’re to about one but on itself help talking an well, of of want in envisioned our results for amount what question big that the is global this for be--for under now anti-fungal efficacy an four, of here just to QX and benefit program, the point us in chime to you’re we patient the payors, sort fully that continue about point out this used impact out, period, as approaching data positioning transition FDA for along so a going hard really talk be strategy team predict When under pleased data QX. means take and during broadest potential an of we’ve asked people getting of you’re MATXXXX, getting period, obviously I we way the go look we occur all-oral encapsulate development cohort we’re time what footprint best convenience for therapy Matkovits you’re of Dr. IV point differentiate, in deal, full and both for the and that being the incredible doing spent a we is IV oral but of based She’s way administration for enrollment, know able circumstances, the and experience that harmonize to to to readout time. the big how on than really convenience, but in is cohort but that for is to - are far. update the fungus. also--with continue anticipate in one, use to is next so will will reporting to of want to the expanding the that’s synergies so to that FDA with economics, Boulware the as on how

Theresa Matkovits

and Thanks Jerry, Bert. for your question, thanks

would to question, feedback your Phase registration trial development we get across as start to really to our global order the to Phase it both regions’ authority the regulatory both the to believe are to harmonize important timing lines we of timing the allow of is and this regulatory that requirements. up be support us year, strategy, meet III on, on in III Just the design gain footprint so trial in and what to with and alignment this European to indicated registration, a very follow global that exactly need the very from well that will of program, optimize you’ve EMA later FDA of able regulatory our

Jerome Jabbour

understand Bert, of treatment are the of And we’re know, we key its necessary that developing everything We’ll of been amphotericin, the in has are all hold data, a and in in here respond to just that, higher be this agent is Fundamentally, drug and all to to The and discussions, at of fungal want now questions global the necessary the a optimize meningitis, this have infections, of you a U.S., build cryptococcal harmony it was end completely asset onto for day inform the infections, to or those a just invasive fungal this those to broad fourth the the prevalence the based ourselves going invasive meningitis about a add year so third fungal drug. purpose us value is potential the here. and were being not doing that dual partner data that able the in strategic outside We total to inputs for and idea franchise in that for everything this interested whether U.S., positioning drug great the foundation. us so and and engage onto FDA package. the of the we quarter key. of in with is will parties with full these alignment but comments interests, had version the taking there really discussions EMA it to invasive here to has so upon because help outside commercializing this including oral we we a of our it who infections. do reach potential safe optimize cryptococcal approach

Bert Hazlett

all for I’ll the Thanks hop back queue. Thanks. that. in

Operator

would please telephone if to one question, on gentlemen, keypad. Ladies like you. you a and Thank your ask press star,

BTIG. from Hazlett with Bert We a question Please ahead. go have

Bert Hazlett

start Thanks. next that evolution beyond the Do your NTM any comments. have infection The previously, regard XXXX, II with NTM? with Then then, to can steps XXXX to indications Phase in missed indications. other for mentioned I for Maybe you’ve when? think you planning I Jerry, regard for about

Jerome Jabbour

Sure. Matkovits light Terry, of with term of some first tox long why Phase in I’ll what’s don’t II? shed Dr. to the question, place studies. position do, really to and has us Bert, to you in put putting necessary start handle the part it that let on sort

Theresa Matkovits

Sure.

with important middle Phase them the early year We development very II days, on three position of on based tox II us to and anticipate our a II initiate development a preliminary year. design, FDA meeting probably to are Phase next for allow XX program, in program. study at share that a duration get trial the to with timelines, would will patients through treatment study quarter two, end Based really Phase treat of in we cover next the currently be quarter our which this alignment our or in thoughts the year of current on the

Jerome Jabbour

data potential so and way Amikacin spectrum was from to for the program are there, that for broad you and to talk just there, the its like really a little generated then the with profile developed his pre-clinical in a there, at Matinas as of trying Mannino reality to impact we’re of in us example haven’t nature efficacy as aminoglycoside be funds. utilizing there, the we of infections. resource been gram anti-fungal aminoglycoside, treatment, to colleagues is negatives, third has by gram and positive recognize and for for not II because Phase start have who talking in the NTM. that, bit as looking pathway of can’t careful Bert, move in unique these you [indiscernible] brought actually viewed who how outside planning for to Bermudes it’s those that don’t indications, forward evaluate made unique for on things space. so particularly so from others, for to And how data it’s profile that’s the that place to and which a the a we like planned is spectrum see towards something oral the fill, been on example, broad half attempted It’s amikacin drugs something in the Fibrosis a to able far natural them, of if other about [ph] Dr. first and just continues that stay perspective, Eugene NTM but to solution UTIs be toxicity - profile. programs possible is this about a to we’re support Cystic of dissimilar sense advance path the drug indications of for in get graveyard parties infections, to potential you The is in of look and the our is of non-dilutive at the we’ll that have to it position. encapsulate also focused of that’s sort eagerly and for bacterial amikacin very to of it with against, with we’re that team the treatment Foundation, NTM their negative the gram for NTM to working both indications much be and ability and the and there the this because was sensitive we closer amphotericin the potential year, The directly is lung, broaden the going a second first use look the of uses NTM then market, we something that’s historically how amikacin logic but the other are aminoglycosides before disseminated

resource we’re certainly not starved resource conscious. We’re but

done both of all the do to our clinical possible of right expand part resources. funds we’ve job indications assets. and stage a right We as continue That’s time, non-dilutive plan. think that, to those our want the with much utilizing then I good as at advance to

Bert Hazlett

thank you Okay, intriguing program that. That’s well. for an as

on thinking LNC press Is the You’re Want advancement to your remdesivir? efforts how sense what a the evolved we the to evolving all love would to collaborations. to ask antibody pandemic that program the want has the published, remdesivir. don’t COVID making we we Just should about on going of and we short as about sure fragment Thank this give material you. number know, understand but of LNC evolution should one, released? - Genentech? in I think last with be LNC plans gone--has shrift broadly ways, urgency to make we data with one progress research of a Just agreement. how potential the of be that get should other different

Jerome Jabbour

announcements. let’s other at each Gilead, do day they we the in be their you of as that confines do in in believe not oral do of to of disclose in Appreciate discussed remdesivir the these it’s similarity. studied and they we’re they turn. of always share work cognizant believe bound as XXX-pound have how they published, important, approaching legally, gorillas, up that terms also within we not those the number questions, - the of different pro-drug But ways. heard be can take when what are is have on future but so we to When a in these With brought They fact Bert. remdesivir, glad so obviously relationships disseminated, to a the much Thanks want we because the of you’re in also have of pre-clinical data developed terms we data a that remdesivir, UNC. both are they of certain with of and what just you in you control and by announced models are will things and and practically sort call that need clear, of of

has of regulatory Ours there. actually version development advantages is so which streamlined enthusiasm oral you as remdesivir, pathways, is obviously think the an about

from For us, NIH. full we need the UNC set and data

histo. on waiting still We’re the

patience; expect and something We the will to Gilead. really drug, a Genentech we’ve point that’s an of of boxes. It an in oral--actual and We discussion really ASO, is of in about of sort certainly hand, it one implications, date. for generated the their the delivered. remdesivir beyond delivery, hand, in for is want successfully got published, challenges. has time, that concept of of efficient to of how a like be small this platform solve to seen at that our do they’ve so it anti-viral already other oral as an at true the is remains has mind, data and Gilead encapsulated a interested has against how a think at oral lot as it’s a at this but delivery under are sort with anti-viral big, We could these looking remdesivir see platform requires number The so engage that fact looking dissimilar this although On with an the broad optimizing to just company, goes oral so delivery demonstration COVID-XX. would the we’ll data they dual data of potential molecule a that checks some with little I we sense an programs. the and already delivery anti-viral, at that that, which all holistically, they’re will across and Genentech least we’ve continuing proof bit path. of and us intracellular a of reengage really so an remdesivir this on Gilead fight not that

to we’re having opportunity else the materials it’s now next team, an for have Just in these from The the alongside everything doing, expanding as activities is - in to breadth. from move an small ASO, these slotting formulation We already the and months. molecules received antibody now Genentech. well is progress few to

That’s that good run this confidentiality, the models, to experience made Gilead, way do the guarantee we it’s then collection, not public, and demonstrated so this, our obligations to we have a that’s work, everything our ability those, in have. Our approaching are our of field. the in and each year their to our that’s over presented, Genentech subject plan it’s and and these up, will our is would back we’ll be own last Genentech this a through to that Genentech, that vitro BioNTech, data data clinical like How that is our with assets, to whether way but has be how whether own it’s real whether in relationships we’ve difference That’s be ever of there with this we far think announced take prepare so do this the and things lining step later showing delivery just year. but we finds to confidence expect programs, when to we’re can maker whether platform, it’s everything with team each is available LNC obviously, successfully. those and stage we a get do

Bert Hazlett

all Thanks that. for

you’re expect more you point? with or BioNTech evolve goal collaboration this follow-up, quick here, that one Is do Genentech collaboration? in Just move the rapidly [indiscernible] with seeing at the this that way a some things will maybe to

Jerome Jabbour

Bert. goal, It’s absolutely a

start goals when different It You concept. have different great of a was proof collaborations. you

from key generating our data perspective of one stamp it point for is value formalize technology from I Genentech with BioNTech of number our a with say, of to The approval that pharma. big brought love that financial relationship to the a and yes, the to, brings. necessary the better We’d relationships think Genentech. maximize with has Genentech, molecules, else get does different a is broad, across sort would is I about anything especially it’s a so us

when great think continue what do great present For somebody directors, ultimately and We’ll experience experience part cemented content seen. continuing potential these remains to with the of data, our and generate collaborations. becoming relationship. that leads is interested and under more has sort in we’re of to be We time, become a that. board our our to the very do to controlling that in of us to that for How

Bert Hazlett

for that. thanks all Terrific,

Operator

remarks. now call have to and and of to and the Thank end for session, reached question the answer Ladies turn the you. gentlemen, back closing Jerry we I like Jabbour would

Jerome Jabbour

investors very our us. valued Peter, thanks who much, been have to loyal and thanks all following and

thrilled which during operating Take strategy position XXXX, a milestones but able next deliver and have you been on the year of We very great of to think and better in, platform. line make progress. with will boxes, we’ve forward apprised catalysts corporate for over keeping in continuing We’re we’re market early to year, care. the cognizant a to balance you look this we delivery having up our check and and our on progress of differentiated the day the recognize of people put to drug value intent us hope

Operator

concludes Thank today’s This you. conference.

you at may You participation. your this disconnect your time. Thank lines for

Matinas BioPharma (MTNB) 12 May 222022 Q1 Earnings call transcript